Class A and C GPCR Dimers in Neurodegenerative Diseases

Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it rema...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current neuropharmacology 2022-01, Vol.20 (11), p.2081-2141
Hauptverfasser: Caniceiro, Ana B, Bueschbell, Beatriz, Schiedel, Anke C, Moreira, Irina S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2141
container_issue 11
container_start_page 2081
container_title Current neuropharmacology
container_volume 20
creator Caniceiro, Ana B
Bueschbell, Beatriz
Schiedel, Anke C
Moreira, Irina S
description Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it remains unclear upon which point a disease turns degenerative. Moreover, current therapeutics can treat some of the symptoms but often have severe side effects and become less effective in long-term treatment. For many neurodegenerative diseases, the involvement of G proteincoupled receptors (GPCRs), which are key players of neuronal transmission and plasticity, has become clearer and holds great promise in elucidating their biological mechanism. With this review, we introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers to increase their signalling repertoire. Additionally, the examples discussed here were shown to display relevant alterations in brain signalling and had already been associated with the pathophysiology of certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories of crosstalk, positive or negative, for which there is known evidence.
doi_str_mv 10.2174/1570159X20666220327221830
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9886835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2644362134</sourcerecordid><originalsourceid>FETCH-LOGICAL-b494t-f301456fab7ba8c1da65afb90abf7199d659441d0a5929fbd46f6f79b1cab0223</originalsourceid><addsrcrecordid>eNp1kU2O1DAQhS0EYoaGK6CwYxPwX-x4gzTqgQFpBAiBxK5kJ5VuQ-IEO-kWF-DcOOqhBQtWLvl9r1x-RcgzRl9wpuVLVmnKKvOVU6UU51RwzTmrBb1HLlmtq1IxQ-_nOnPlCl6QRyl9o5RXNdcPyYWohDBM60uit71NqbgqbGiLbXHzcfupuPYDxlT4ULzHJY4t7jBgtLM_YNYS2oTpMXnQ2T7hk7tzQ768ef15-7a8_XDzbnt1Wzpp5Fx2gjJZqc467WzdsNaqynbOUOs6zYxpVWWkZC21leGmc61Uneq0cayxjnIuNuTVqe-0uAHbBsMcbQ9T9IONP2G0Hv5Vgt_DbjyAqWtV539uyPO7BnH8sWCaYfCpwb63AcclAVdSCsWZkBk1J7SJY0oRu_MzjMIaPPw3-Ox9-vecZ-efpDPw6wS4POjeDqnxGBo8g_t5nuB4PEKOHL_niHtsZmjGAcYJwxL7XIc5e2HaT5A3EhFsnH3TI_iUAqyLh3XxcBj7ZUDgdBUWBMYgTXa33tRM_AZZULGv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644362134</pqid></control><display><type>article</type><title>Class A and C GPCR Dimers in Neurodegenerative Diseases</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Caniceiro, Ana B ; Bueschbell, Beatriz ; Schiedel, Anke C ; Moreira, Irina S</creator><creatorcontrib>Caniceiro, Ana B ; Bueschbell, Beatriz ; Schiedel, Anke C ; Moreira, Irina S</creatorcontrib><description>Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it remains unclear upon which point a disease turns degenerative. Moreover, current therapeutics can treat some of the symptoms but often have severe side effects and become less effective in long-term treatment. For many neurodegenerative diseases, the involvement of G proteincoupled receptors (GPCRs), which are key players of neuronal transmission and plasticity, has become clearer and holds great promise in elucidating their biological mechanism. With this review, we introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers to increase their signalling repertoire. Additionally, the examples discussed here were shown to display relevant alterations in brain signalling and had already been associated with the pathophysiology of certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories of crosstalk, positive or negative, for which there is known evidence.</description><identifier>ISSN: 1570-159X</identifier><identifier>EISSN: 1875-6190</identifier><identifier>DOI: 10.2174/1570159X20666220327221830</identifier><identifier>PMID: 35339177</identifier><language>eng</language><publisher>United Arab Emirates: Bentham Science Publishers Ltd</publisher><subject>Aged ; Brain - metabolism ; Humans ; Neurodegenerative Diseases ; Neurology ; Receptors, G-Protein-Coupled - metabolism ; Signal Transduction ; Synaptic Transmission</subject><ispartof>Current neuropharmacology, 2022-01, Vol.20 (11), p.2081-2141</ispartof><rights>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</rights><rights>2022 Bentham Science Publishers 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-b494t-f301456fab7ba8c1da65afb90abf7199d659441d0a5929fbd46f6f79b1cab0223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886835/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886835/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35339177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caniceiro, Ana B</creatorcontrib><creatorcontrib>Bueschbell, Beatriz</creatorcontrib><creatorcontrib>Schiedel, Anke C</creatorcontrib><creatorcontrib>Moreira, Irina S</creatorcontrib><title>Class A and C GPCR Dimers in Neurodegenerative Diseases</title><title>Current neuropharmacology</title><addtitle>CN</addtitle><description>Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it remains unclear upon which point a disease turns degenerative. Moreover, current therapeutics can treat some of the symptoms but often have severe side effects and become less effective in long-term treatment. For many neurodegenerative diseases, the involvement of G proteincoupled receptors (GPCRs), which are key players of neuronal transmission and plasticity, has become clearer and holds great promise in elucidating their biological mechanism. With this review, we introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers to increase their signalling repertoire. Additionally, the examples discussed here were shown to display relevant alterations in brain signalling and had already been associated with the pathophysiology of certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories of crosstalk, positive or negative, for which there is known evidence.</description><subject>Aged</subject><subject>Brain - metabolism</subject><subject>Humans</subject><subject>Neurodegenerative Diseases</subject><subject>Neurology</subject><subject>Receptors, G-Protein-Coupled - metabolism</subject><subject>Signal Transduction</subject><subject>Synaptic Transmission</subject><issn>1570-159X</issn><issn>1875-6190</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU2O1DAQhS0EYoaGK6CwYxPwX-x4gzTqgQFpBAiBxK5kJ5VuQ-IEO-kWF-DcOOqhBQtWLvl9r1x-RcgzRl9wpuVLVmnKKvOVU6UU51RwzTmrBb1HLlmtq1IxQ-_nOnPlCl6QRyl9o5RXNdcPyYWohDBM60uit71NqbgqbGiLbXHzcfupuPYDxlT4ULzHJY4t7jBgtLM_YNYS2oTpMXnQ2T7hk7tzQ768ef15-7a8_XDzbnt1Wzpp5Fx2gjJZqc467WzdsNaqynbOUOs6zYxpVWWkZC21leGmc61Uneq0cayxjnIuNuTVqe-0uAHbBsMcbQ9T9IONP2G0Hv5Vgt_DbjyAqWtV539uyPO7BnH8sWCaYfCpwb63AcclAVdSCsWZkBk1J7SJY0oRu_MzjMIaPPw3-Ox9-vecZ-efpDPw6wS4POjeDqnxGBo8g_t5nuB4PEKOHL_niHtsZmjGAcYJwxL7XIc5e2HaT5A3EhFsnH3TI_iUAqyLh3XxcBj7ZUDgdBUWBMYgTXa33tRM_AZZULGv</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Caniceiro, Ana B</creator><creator>Bueschbell, Beatriz</creator><creator>Schiedel, Anke C</creator><creator>Moreira, Irina S</creator><general>Bentham Science Publishers Ltd</general><general>Bentham Science Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>Class A and C GPCR Dimers in Neurodegenerative Diseases</title><author>Caniceiro, Ana B ; Bueschbell, Beatriz ; Schiedel, Anke C ; Moreira, Irina S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b494t-f301456fab7ba8c1da65afb90abf7199d659441d0a5929fbd46f6f79b1cab0223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Brain - metabolism</topic><topic>Humans</topic><topic>Neurodegenerative Diseases</topic><topic>Neurology</topic><topic>Receptors, G-Protein-Coupled - metabolism</topic><topic>Signal Transduction</topic><topic>Synaptic Transmission</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caniceiro, Ana B</creatorcontrib><creatorcontrib>Bueschbell, Beatriz</creatorcontrib><creatorcontrib>Schiedel, Anke C</creatorcontrib><creatorcontrib>Moreira, Irina S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caniceiro, Ana B</au><au>Bueschbell, Beatriz</au><au>Schiedel, Anke C</au><au>Moreira, Irina S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Class A and C GPCR Dimers in Neurodegenerative Diseases</atitle><jtitle>Current neuropharmacology</jtitle><addtitle>CN</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>20</volume><issue>11</issue><spage>2081</spage><epage>2141</epage><pages>2081-2141</pages><issn>1570-159X</issn><eissn>1875-6190</eissn><abstract>Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it remains unclear upon which point a disease turns degenerative. Moreover, current therapeutics can treat some of the symptoms but often have severe side effects and become less effective in long-term treatment. For many neurodegenerative diseases, the involvement of G proteincoupled receptors (GPCRs), which are key players of neuronal transmission and plasticity, has become clearer and holds great promise in elucidating their biological mechanism. With this review, we introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers to increase their signalling repertoire. Additionally, the examples discussed here were shown to display relevant alterations in brain signalling and had already been associated with the pathophysiology of certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories of crosstalk, positive or negative, for which there is known evidence.</abstract><cop>United Arab Emirates</cop><pub>Bentham Science Publishers Ltd</pub><pmid>35339177</pmid><doi>10.2174/1570159X20666220327221830</doi><tpages>61</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1570-159X
ispartof Current neuropharmacology, 2022-01, Vol.20 (11), p.2081-2141
issn 1570-159X
1875-6190
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9886835
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Aged
Brain - metabolism
Humans
Neurodegenerative Diseases
Neurology
Receptors, G-Protein-Coupled - metabolism
Signal Transduction
Synaptic Transmission
title Class A and C GPCR Dimers in Neurodegenerative Diseases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T06%3A34%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Class%20A%20and%20C%20GPCR%20Dimers%20in%20Neurodegenerative%20Diseases&rft.jtitle=Current%20neuropharmacology&rft.au=Caniceiro,%20Ana%20B&rft.date=2022-01-01&rft.volume=20&rft.issue=11&rft.spage=2081&rft.epage=2141&rft.pages=2081-2141&rft.issn=1570-159X&rft.eissn=1875-6190&rft_id=info:doi/10.2174/1570159X20666220327221830&rft_dat=%3Cproquest_pubme%3E2644362134%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2644362134&rft_id=info:pmid/35339177&rfr_iscdi=true